Goldman Sachs’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-395,271
| Closed | -$3.55M | – | 7373 |
|
|
2016
Q3 | $3.55M | Sell |
395,271
-2,358,228
| -86% | -$16.8M | ﹤0.01% | 3349 |
|
|
2016
Q2 | $14.8M | Buy |
2,753,499
+98,734
| +4% | +$506K | ﹤0.01% | 2016 |
|
|
2016
Q1 | $12.2M | Buy |
2,654,765
+679
| +0% | +$2.73K | ﹤0.01% | 2076 |
|
|
2015
Q4 | $13.8M | Sell |
2,654,086
-8,178
| -0.3% | -$47.5K | ﹤0.01% | 2011 |
|
|
2015
Q3 | $16.1M | Sell |
2,662,264
-57,386
| -2% | -$703K | 0.01% | 1879 |
|
|
2015
Q2 | $42.9M | Buy |
2,719,650
+121,896
| +5% | +$1.48M | 0.01% | 1220 |
|
|
2015
Q1 | $28.2M | Buy |
2,597,754
+180,368
| +7% | +$1.84M | 0.01% | 1518 |
|
|
2014
Q4 | $25.4M | Buy |
2,417,386
+544,866
| +29% | +$5.32M | 0.01% | 1651 |
|
|
2014
Q3 | $18M | Sell |
1,872,520
-2,002,662
| -52% | -$20.5M | 0.01% | 1866 |
|
|
2014
Q2 | $44.8M | Buy |
3,875,182
+1,074,427
| +38% | +$9.78M | 0.01% | 1188 |
|
|
2014
Q1 | $28M | Sell |
2,800,755
-90,400
| -3% | -$1.31M | 0.01% | 1492 |
|
|
2013
Q4 | $37.6M | Buy |
2,891,155
+2,878,358
| +22,492% | +$39.6M | 0.01% | 1264 |
|
|
2013
Q3 | $191K | Sell |
12,797
-14,765
| -54% | -$177K | ﹤0.01% | 5904 |
|
|
2013
Q2 | $258K | Buy |
+27,562
| New | +$187K | ﹤0.01% | 5421 |
|
Goldman Sachs's RPTP Position: Q4 2016 in Review
Goldman Sachs sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q4 2016, closing a stake of 395,271 shares — an estimated $3.55M sold.
Goldman Sachs first reported a position in RPTP in Q2 2013 and held it in 14 quarters. The position peaked at $44.8M in Q2 2014. 0 funds tracked by Wall St. Rank hold RPTP as of Q4 2016.
- Goldman Sachs reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q4 2016 after selling out during the quarter.
- Goldman Sachs sold 395,271 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q4 2016, an estimated $3.55M.
- Goldman Sachs first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2013 and held it in 14 quarters.
- Goldman Sachs's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $44.8M in Q2 2014.
- 0 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q4 2016.
Based on Goldman Sachs's 13F filing for Q4 2016, filed 14 Feb 2017.